Table 1.
Sample characteristic at time 1 and follow-ups (N = 95)
| Baseline Time 1 |
Follow-up Time 2 |
Follow-up Time 3 |
|
|---|---|---|---|
| M (SD) or % | |||
|
| |||
| Age | 13.4 (0.7) | 15.1 (.9) | 19.8 (.9) |
| % Female | 47.4% | ||
| Hollingshead Index (SES) | 22.1 (12.7) | ||
| Family History | |||
| Negative | 43.6% | ||
| Mild | 34.0% | ||
| Positive | 22.3% | ||
| Race | |||
| Latino/a | 20.0% | ||
| Caucasian | 68.4% | ||
| African-American | 3.2% | ||
| Asian | 6.3% | ||
| Other | 5.3% | ||
| Multiple races | 16.8% | ||
| % Conduct disorder | 3.2% | ||
| Sleepiness a | 13.2 (2.9) | ||
| Erratic sleep/wake behaviors a | 14.6 (4.0) | ||
| Chronotype a | 28.2 (4.9) | ||
| % Lifetime tobacco users | 0% | 54.7% | |
| % Lifetime drinkers | 0% | 100% | |
| % Lifetime cannabis users | 0% | 57.9% | |
| % Other recreational drug users b | 0% | 22.1% | |
| Past year drinking days | 0 (0.0) | 43.6 (55.3) | |
| Past year HED days | 0 (0.0) | 17.9 (35.6) | |
| Average monthly drinking days * | 0 (0.0) | 3.6 (4.5) | |
a
Sleep Habits Questionnaire scale score, higher values indicate more sleepiness, more erratic sleep/wake behaviors, and greater morning chronotype tendency
b
Amphetamines, barbiturates, hallucinogens, cocaine, inhalants, opiates, benzodiazepines, ecstasy, ketamine, gamma-Hydroxybutyric acid [GHB], and Phencyclidine [PCP]
*
Past 3 months